| Restoration of euthyroidism does not improve cardiovascular risk factors in patients with subclinical hypothyroidism in the short term. | |
| | |
MedLine Citation:
|
PMID: 16840827 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Subclinical hypothyroidism (SH) is being accepted as a condition that is associated with increased risk of cardiovascular disease. Restoration of euthyroidism might be involved in prevention of cardiovascular disease. Thus, we evaluated biochemical risk factors of 75 patients with SH without evidence of any other diseases before and after restoration of euthyroidism and compared to 27 healthy controls. Before and a mean of 18.2+/-4.4 weeks after restoration of euthyroidism, serum total and LDL cholesterol, lipoprotein (Lp) (a), total homocysteine (t-Hyc) and highly sensitive C-reactive protein (hsCRP) levels were analyzed. Pre-treatment levels of TSH (10.04+/-5.36 vs 1.74+/-1.1 mIU/l, p<0.05), total cholesterol (204+/-68 vs 179+/-26 mg/dl, p<0.05) and LDL cholesterol (129+/-50 vs 106+/-16 mg/dl, p<0.05) were significantly higher than controls while Lp (a), t-Hyc, and hsCRP levels were not different. None of these biochemical risk factors have improved after euthyroidism in patients with SH with average dose of 85+/-30 microg/day, when compared to pre-treatment levels. Only in a subgroup of patients (no. 30) with higher TSH levels (>10 mIU/l), did serum LDL cholesterol levels decrease significantly (139+/-38 vs 112+/-35 mg/dl, p<0.05). Lp (a), t-Hyc and hsCRP levels were not significantly different after treatment with levothyroxine therapy even in this subgroup of patients. We conclude that clinical management of SH does not contribute to prevention of cardiovascular disease in the short term, and monitoring risk factors of cardiovascular disease does not offer additional benefits for treating patients with SH. |
| | |
Authors:
|
Z Beyhan; K Ertürk; G Uçkaya; E Bolu; H Yaman; M Kutlu |
Related Documents
:
|
18317847 - Why don't diabetes patients achieve recommended risk factor targets? poor adherence ver... 3803417 - Acipimox in the treatment of patients with hyperlipidaemia: a double blind trial. 22621797 - A new scoring system for evaluating the risk of heart failure events in japanese patien... 21985337 - Kcne5 polymorphism rs697829 is associated with qt interval and survival in acute corona... 9098407 - A shared hla-drb1 sequence confers ra susceptibility in greeks. 18317847 - Why don't diabetes patients achieve recommended risk factor targets? poor adherence ver... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of endocrinological investigation Volume: 29 ISSN: 0391-4097 ISO Abbreviation: J. Endocrinol. Invest. Publication Date: 2006 Jun |
Date Detail:
|
Created Date: 2006-07-14 Completed Date: 2006-08-24 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7806594 Medline TA: J Endocrinol Invest Country: Italy |
Other Details:
|
Languages: eng Pagination: 505-10 Citation Subset: IM |
Affiliation:
|
Department of Endocrinology and Metabolism, Gulhane School of Medicine, 06018 Etlik, Ankara, Turkey. zbeyhan@gata.edu.tr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult C-Reactive Protein / metabolism Cardiovascular Diseases / etiology* Cholesterol / blood Female Homocysteine / blood Humans Hypothyroidism / complications, drug therapy* Lipoprotein(a) / blood Lipoproteins, LDL / blood Male Middle Aged Risk Factors Thyrotropin / blood Thyroxine / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Lipoprotein(a); 0/Lipoproteins, LDL; 454-28-4/Homocysteine; 57-88-5/Cholesterol; 7488-70-2/Thyroxine; 9002-71-5/Thyrotropin; 9007-41-4/C-Reactive Protein |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Improvement of metabolic syndrome markers through altitude specific hiking vacations.
Next Document: A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of pati...